newsfilter
← Latest News
PR Newswire·

Briefing Book for ODAC meeting on benefit/risk profile of Pepaxto now published

STOCKHOLM, Sept. 20, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (NASDAQ:ONCO) (Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the US Food and Drug